The business model and services provided by both private and public healthcare institutions are becoming inefficient in addressing the needs of humans living in an ever-accelerating world. Expensive methodologies combined with slow research and development processes lead to a lack of incentives for innovation in the field.
For over 10 years, Sthorm has been connecting communities and public healthcare providers with innovative ways of funding and advancing impactful scientific research.
Our ViralCure platform has raised over 20 million USD in support of São Paulo's Hospital das Clínicas (the largest community health center in the Global South).
MABLOC, our first biotech, has developed a Broadly Reactive Antibody Isolation and Development (BRAID) platform, accelerating the discovery of high-end biopharmaceuticals against Yellow Fever, Dengue, Zika, and many other neglected tropical diseases.
LiqSci is introducing fast and affordable diagnostics to prevent breast cancer, diabetic nephropathy, and other maladies that affect millions in underserved populations.
ImmunoX, a third early-stage biotech supported by Sthorm, is pioneering the use of CAR-M cell therapy to treat a variety of oncologic conditions for which no other treatments are available.